You are here:--
Antibacterial drugs: Clinical development for non-developers
Part 3: Non-traditional approaches


Antibacterial drugs: Clinical development for non-developers
Part 3: Non-traditional approaches


Moderator: David Shlaes, Anti-infectives consulting, retired

Speakers:

  • Ian Friedland, Clinical consultant, Friedland Strategic Consulting, LLC
  • Sumathi Nambiar, Director, Division of Anti-Infective Products, Office of Antimicrobial Products, CDER, FDA
  • Mair Powell, Senior Clinical Assessor, Health Products Regulatory Authority (Ireland)

The overall goal of this series of webinars is to provide, for the non-clinical developer, an understanding of the risks of development for various kinds of antibacterial products. Our first webinar was devoted to more traditional approaches (Tiers A and B), best suited for more broad-spectrum products, where the risks are lower. In the second webinar, we discussed the development of products that target a single species of bacteria where the risks may be higher. In this third webinar, we discussed non-traditional approaches for antibiotic development.


This live webinar including interactive Q&A session was broadcast on 28 March 2019.

If you have questions or comments, please let us know. Do so by posting them in our forum or submitting them via the ‘Talk to an expert’ feature. You can also send questions to: info.revive@dndi.org.

2019-07-11T07:49:02+00:00